Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy
Interventions
DRUG

Salbutamol 400mcg

Salbutamol is a short-acting beta-agonist used primarily as a rescue inhaler for respiratory disease such as asthma

DRUG

Budesonide/formoterol

Budesonide/formoterol is a inhaled corticosteroid with long-acting beta-agonist component primarily used as a maintenance inhaler for respiratory conditions such as asthma

DRUG

Placebo

Practice inhaler primarily used in training scenarios so looks identical to medical inhalers

Trial Locations (1)

T6G2R3

Clinical Physiology Laboratory, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT06027606 - Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use | Biotech Hunter | Biotech Hunter